MissionIR would like to highlight
International Stem Cell Corporation (
OTCQB: ISCO), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.
In the company’s news,
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, recently announced that it has entered into an agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson’s patients. The Florey is viewed by the medical community as one of the world’s leading brain research centers. With the largest neuroscience research team in Australia at its side, both parties’ collaborative efforts are now underway.
Director of the Movement Disorders Service at the Royal Melbourne Hospital, Dr. Andrew Evans, M.D., has assumed the duties that come with being named the study’s principal investigator. Dr. Evans has published extensively on Parkinson’s, addressing symptoms while leading several clinical research trials.
“We recently received authorization to initiate Phase I/IIa and now we are moving forward towards formal engagement of the clinical site to conduct this study. We are excited to work together with the Florey to conduct the clinical trials of ISC-hpNSC at the Royal Melbourne Hospital,” commented Russell Kern, PhD, executive vice president and chief scientific officer at International Stem Cell Corporation. “We expect to enroll all patients into the clinical trial in Q1 2016 and provide interim results in October 2016.”
ISC-hpNSC consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC are a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants.
ISCO’s resources and efforts are aimed at therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. Parthenogenesis, ISCO’s core technology, results in the creation of pluripotent human stem cells from unfertilized oocytes. hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. Company scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of various genders, ages and racial backgrounds with minimal immune rejection after transplantation.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
